Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
Latrogenic infertility as a result of cancer treatment has a profound effect on long-term
quality of life in survivors of reproductive-age cancers. Oocyte cryopreservation prior to
cancer treatment has been associated with improved quality of life, with a potential ability
to reduce long-term decision-related regret in cancer survivors. Though letrozole plus
gonadotropin and and tamoxifen plus gonadotropin are currently routinely used worldwide in
ovarian stimulation cycles for fertility preservation in patients with
estrogen-receptor-positive breast cancer, it is not clear which of the two might lead to
improved oocyte yield. Improved knowledge about the efficacy of these medications, with
regard to oocyte yield, has the potential to significantly improve quality of life in
reproductive-age breast cancer survivors.